M Caraglia
Overview
Explore the profile of M Caraglia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
1915
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giallongo C, Dulcamare I, Giallongo S, Duminuco A, Pieragostino D, Cufaro M, et al.
Cell Death Dis
. 2023 Oct;
14(10):686.
PMID: 37852977
Ineffective hematopoiesis is a hallmark of myelodysplastic syndromes (MDS). Hematopoietic alterations in MDS patients strictly correlate with microenvironment dysfunctions, eventually affecting also the mesenchymal stromal cell (MSC) compartment. Stromal cells...
2.
Nigro E, Stiuso P, Matera M, Monaco M, Caraglia M, Maniscalco M, et al.
Pulm Pharmacol Ther
. 2019 Jan;
55:25-30.
PMID: 30654148
Adiponectin (Acrp30) plays an important role in energy metabolism and inflammation. Recently, in vivo serum Acrp30 levels have been reported to be correlated to risk of developing several types of...
3.
Orditura M, Della Corte C, Diana A, Ciaramella V, Franzese E, Famiglietti V, et al.
Breast
. 2018 Aug;
41:165-171.
PMID: 30103105
Two inhibitors of phosphatidylinositol 3-kinase (PI3K) pathway taselisib, targeting the mutant PI3K-subunit-alpha (PI3KA) and ipatasertib, AKT-inhibitor, are currently under clinical investigation in breast cancer (BC) patients. We have previously demonstrated...
4.
Ricciardiello F, Capasso R, Kawasaki H, Abate T, Oliva F, Lombardi A, et al.
Acta Otorhinolaryngol Ital
. 2018 Jan;
37(6):467-474.
PMID: 29327732
The discovery that miRNAs are frequently deregulated in tumours offers the opportunity to identify them as prognostic and diagnostic markers. The aim of this multicentric study is to identify a...
5.
Giudice A, Montella M, Boccellino M, Crispo A, DArena G, Bimonte S, et al.
Curr Mol Med
. 2017 Dec;
17(6):405-420.
PMID: 29256350
Prostate cancer is one of the most difficult cancers to treat especially when it becomes hormone resistant such as castrate resistant prostate cancer (CRPC) and subsequent metastatic CRPC. Apart from...
6.
Dicitore A, Grassi E, Borghi M, Gelmini G, Cantone M, Gaudenzi G, et al.
J Endocrinol Invest
. 2017 Mar;
40(7):761-770.
PMID: 28247216
Purpose: Type I interferons (IFN-α and IFN-β) are a class of cytokines that exert several biological activities, such as modulation of cell proliferation and differentiation and of the immune system....
7.
Zappavigna S, Scuotto M, Cossu A, Ingrosso D, de Rosa M, Schiraldi C, et al.
J Exp Clin Cancer Res
. 2016 Oct;
35(1):167.
PMID: 27770821
Background: Embelin is a potent dual inhibitor of 5-lipoxigenase (5-LOX) and microsomal prostaglandin E2 synthase (mPGES)-1 that suppresses proliferation of human glioma cells and induces apoptosis by inhibiting XIAP and...
8.
Martino E, Misso G, Pastina P, Costantini S, Vanni F, Gandolfo C, et al.
Cell Death Discov
. 2016 Oct;
2:16025.
PMID: 27752361
The mPEBev is an anticancer regimen which combines a chemotherapy doublet, based on cisplatin and oral etoposide (mPE), with bevacizumab (mPEBev), a mAb targeting the vasculo-endothelial growth factor (VEGF). In...
9.
Botta C, Misso G, Martino E, Pirtoli L, Cusi M, Tassone P, et al.
Cell Death Dis
. 2016 Jul;
7:e2299.
PMID: 27441651
No abstract available.
10.
Salzano G, Zappavigna S, Luce A, DOnofrio N, Balestrieri M, Grimaldi A, et al.
J Biomed Nanotechnol
. 2016 Jun;
12(4):811-30.
PMID: 27301207
The treatment of glioblastoma (GBM) is a challenge for the biomedical research since cures remain elusive. Its current therapy, consisted on surgery, radiotherapy, and concomitant chemotherapy with temozolomide (TMZ), is...